Resource Type

Journal Article 120

Year

2024 1

2023 9

2022 20

2021 6

2020 9

2019 10

2018 7

2017 7

2016 4

2015 6

2014 5

2013 3

2012 2

2011 2

2010 3

2009 9

2008 5

2007 3

2006 2

2005 1

open ︾

Keywords

immunotherapy 7

COVID-19 5

immune checkpoint inhibitor 4

PD-L1 3

SARS-CoV-2 3

lung cancer 3

DNA damage 2

PD-1 2

apoptosis 2

hypertension 2

immune escape 2

immune response 2

resistance 2

tyrosine kinase inhibitor 2

3D printing 1

4-1BB ligand 1

Hevea brasiliensis 1

Neospora caninum 1

ADAM10 inhibitor 1

open ︾

Search scope:

排序： Display mode:

Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 307-321 doi: 10.1007/s11684-022-0927-0

Abstract: The discovery of immune checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4, has played an importantcheckpoint inhibitors.Clinical practice has revealed that antibiotics can weaken the therapeutic response to immune checkpointStudies have shown that the gut microbiota is essential for the interaction between immune checkpointThis review focuses on the interactions between immune checkpoint inhibitors and antibiotics, with an

Keywords： tumor immunotherapy     immune checkpoint inhibitor     antibiotics     gut microbiota     drug–drug interaction    

HTML PDF Collect

Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 773-783 doi: 10.1007/s11684-021-0902-1

Abstract: The total number of cancer patients who are eligible for and will benefit from immune checkpoint inhibitorspatients with eligibility and response to ICIs based on the 2015 Chinese cancer statistics and the immunecheckpoint inhibitor clinical practice guideline of the Chinese Society of Clinical Oncology.

Keywords： benefit     China     eligibility     immune checkpoint inhibitor     public health    

HTML PDF Collect

Immunometabolism: a new dimension in immunotherapy resistance

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 585-616 doi: 10.1007/s11684-023-1012-z

Abstract: Immune checkpoint inhibitors (ICIs) have demonstrated unparalleled clinical responses and revolutionizedof metabolic intervention with ICIs to reap synergic benefits and facilitate an adjusted anti-tumor immune

Keywords： immune cell     immunometabolism     metabolic reprogramming     immunotherapy     resistance     tumor microenvironment     immune checkpoint inhibitor    

HTML PDF Collect

Challenges of NK cell-based immunotherapy in the new era

Fang Fang, Weihua Xiao, Zhigang Tian

Frontiers of Medicine 2018, Volume 12, Issue 4,   Pages 440-450 doi: tzg@ustc.edu.cn

Abstract:

Natural killer cells (NKs) have a great potential for cancer immunotherapy because they can rapidly and directly kill transformed cells in the absence of antigen presensitization. Various cellular sources, including peripheral blood mononuclear cells (PBMCs), stem cells, and NK cell lines, have been used for producing NK cells. In particular, NK cells that expanded from allogeneic PBMCs exhibit better efficacy than those that did not. However, considering the safety, activities, and reliability of the cell products, researchers must develop an optimal protocol for producing NK cells from PBMCs in the manufacture setting and clinical therapeutic regimen. In this review, the challenges on NK cell-based therapeutic approaches and clinical outcomes are discussed.

Keywords： natural killer cells     immunotherapy     adoptive transfer     genetic modification     immune checkpoint inhibitor    

HTML Collect

Advances on immune-related adverse events associated with immune checkpoint inhibitors

Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang

Frontiers of Medicine 2021, Volume 15, Issue 1,   Pages 33-42 doi: 10.1007/s11684-019-0735-3

Abstract: Immunotherapy has recently led to a paradigm shift in cancer therapy, in which immune checkpoint inhibitorsnon-specific activation of effector T cells, ICIs are remarkably associated with a substantial risk of immune-related

Keywords： cancer     immunotherapy     immune checkpoint inhibitors     immune-related adverse events     review    

HTML PDF Collect

Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases

Zhen Xiang, Yingyan Yu

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 24-31 doi: 10.1007/s11684-019-0679-7

Abstract: Immune checkpoint inhibitors are a promising strategy in the treatment of cancer, especially advancedHowever, not all patients are responsive to immune checkpoint inhibitors.of immune checkpoint proteins, and molecular subtypes of cancers.checkpoint inhibitors.overcoming resistance, and indications for immune checkpoint inhibitor therapy.

Keywords： immune checkpoint blockade     sensitivity     resistance     data mining    

HTML PDF Collect

Molecular classification and precision therapy of cancer: immune checkpoint inhibitors

Yingyan Yu

Frontiers of Medicine 2018, Volume 12, Issue 2,   Pages 229-235 doi: 10.1007/s11684-017-0581-0

Abstract: MSI-H status due to dMMR and characterized by increased neoantigen load, which elicits intense host immune

Keywords： molecular classification     precision medicine     pembrolizumab     PD-1/PD-L1     MSI-H    

HTML PDF Collect

Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects

Chenfei Zhou, Jun Zhang

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 12-23 doi: 10.1007/s11684-019-0685-9

Abstract: The efficacy of immune checkpoint inhibitors (ICIs) for treatment of refractory GI cancer has been confirmedThis review discusses the current status of combining immune checkpoint inhibitors with molecular targeted

Keywords： gastrointestinal cancer     immune checkpoint inhibitor     combination therapy    

HTML PDF Collect

Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient

Frontiers of Medicine 2022, Volume 16, Issue 4,   Pages 596-609 doi: 10.1007/s11684-021-0868-z

Abstract: Sialic acid binding Ig-like lectin 10 (Siglec10) is a member of innate immune checkpoints that inhibitsthe activation of immune cells through the interaction with its ligand CD24 on tumor cells.

Keywords： innate immune checkpoint     Siglec10     kidney renal clear cell carcinoma    

HTML PDF Collect

Liver-directed treatment is associated with improved survival and increased response to immune checkpoint

Frontiers of Medicine   Pages 878-888 doi: 10.1007/s11684-023-0993-y

Abstract: A total of 182 patients with metastatic UM treated with immune checkpoint blockade (ICB) were included

Keywords： uveal melanoma     liver-directed therapy     immune checkpoint blockade     SIRT     anti-PD-1     anti-CTLA-4    

HTML PDF Collect

Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy

Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 32-44 doi: 10.1007/s11684-018-0678-0

Abstract: In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overallHowever, inhibitor therapies are only effective in a small proportion of patients with problems, suchTherefore, doctors urgently need reliable predictive biomarkers for checkpoint inhibitor therapies toHere, we review the biomarkers that can serve as potential predictors of the outcomes of immune checkpointinhibitor treatment, including tumor-specific profiles and tumor microenvironment evaluation and other

Keywords： immune checkpoint     companion diagnosis     PD-L1     tumor mutation burden     immune score    

HTML PDF Collect

Activation of phagocytosis by immune checkpoint blockade

Chia-Wei Li, Yun-Ju Lai, Jennifer L. Hsu, Mien-Chie Hung

Frontiers of Medicine 2018, Volume 12, Issue 4,   Pages 473-480 doi: 10.1007/s11684-018-0657-5

Abstract:

Inhibition of macrophage-mediated phagocytosis has emerged as an essential mechanism for tumor immuneAs more and more immune receptors are found to be expressed on TAMs, the corresponding therapies may

Keywords： CD47     PD-1     PD-L1     immunotherapy     TAM     phagocytosis     macrophage    

HTML PDF Collect

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions

Frontiers of Medicine 2023, Volume 17, Issue 1,   Pages 18-42 doi: 10.1007/s11684-022-0976-4

Abstract: Furthermore, the therapeutic role of immune-checkpoint inhibitors (ICIs) in oncogene-driven NSCLC remainsdriver mutations and the combined therapeutic approaches that might reverse the immunosuppressive tumor immune

Keywords： non-small cell lung cancer     driver mutations     treatment strategy     resistant mechanism     immune-checkpoint    

HTML PDF Collect

PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives

Yumeng Wang, Guiling Li

Frontiers of Medicine 2019, Volume 13, Issue 4,   Pages 438-450 doi: 10.1007/s11684-018-0674-4

Abstract: recent years, exciting progress has been made in immunotherapies, including the rapid development of immunecheckpoint inhibitors.Checkpoint blockades targeting the PD-1/PD-L1 axis have achieved effective clinical responses with acceptable

Keywords： PD-1     PD-L1     immune checkpoint blockade antibody     immunotherapy     cervical cancer    

HTML PDF Collect

Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies

Frontiers of Medicine   Pages 805-822 doi: 10.1007/s11684-023-1025-7

Abstract: Immunotherapies based on immune checkpoint blockade (ICB) have significantly improved patient outcomesTo date, immune checkpoint inhibitors (ICIs) of CTLA-4 and PD-1/PD-L1 represent the main class of immunotherapyRecently, numerous studies have revealed that metabolic reprogramming of tumor cells restrains immuneHere, we demonstrate the generalized mechanism of targeting cancer metabolism at three crucial immuneand propose potential combined immunotherapeutic strategies co-targeting tumor metabolic pathways and immune

Keywords： CTLA-4     PD-1     PD-L1     immune checkpoint blockade (ICB)     metabolic reprogramming     combined tumor therapeutic    

HTML PDF Collect

Title Author Date Type Operation

Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy

Journal Article

Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors

Journal Article

Immunometabolism: a new dimension in immunotherapy resistance

Journal Article

Challenges of NK cell-based immunotherapy in the new era

Fang Fang, Weihua Xiao, Zhigang Tian

Journal Article

Advances on immune-related adverse events associated with immune checkpoint inhibitors

Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang

Journal Article

Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases

Zhen Xiang, Yingyan Yu

Journal Article

Molecular classification and precision therapy of cancer: immune checkpoint inhibitors

Yingyan Yu

Journal Article

Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects

Chenfei Zhou, Jun Zhang

Journal Article

Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient

Journal Article

Liver-directed treatment is associated with improved survival and increased response to immune checkpoint

Journal Article

Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy

Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian

Journal Article

Activation of phagocytosis by immune checkpoint blockade

Chia-Wei Li, Yun-Ju Lai, Jennifer L. Hsu, Mien-Chie Hung

Journal Article

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions

Journal Article

PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives

Yumeng Wang, Guiling Li

Journal Article

Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies

Journal Article